Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15

Core Insights - Silo Pharma has entered into a non-binding Letter of Intent with Allucent to conduct two Phase 1 studies for its SPC-15 nasal spray targeting PTSD and anxiety [1][2][3] Group 1: Clinical Development - The planned studies include an Open-Label, Single Ascending Dose (SAD) study and an Open-Label, Multiple Ascending Dose (MAD) study [1] - The collaboration with Allucent aims to leverage their expertise in clinical operations, pharmacovigilance, data management, and other areas to support the execution of the Phase 1 program [2][3] Group 2: Product Information - SPC-15 is an investigational intranasal serotonin 5-HT4 receptor agonist designed for stress-induced psychiatric conditions, primarily PTSD and anxiety, utilizing a soft mist nasal spray for rapid brain action [4] - The product is in preclinical stages and is being developed in partnership with Columbia University, with plans for an accelerated FDA approval pathway [4] Group 3: Company Overview - Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company focused on addressing underserved conditions such as stress-induced psychiatric disorders and chronic pain [5] - The company's portfolio includes other innovative programs targeting fibromyalgia, chronic pain, Alzheimer's disease, and multiple sclerosis [5]